Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.

Han SN, Sun XY, Zhang Z, Zhang LR.

Acta Pharmacol Sin. 2015 Apr;36(4):454-62. doi: 10.1038/aps.2014.165. Epub 2015 Mar 23.

2.

Inside job: ligand-receptor pharmacology beneath the plasma membrane.

Babcock JJ, Li M.

Acta Pharmacol Sin. 2013 Jul;34(7):859-69. doi: 10.1038/aps.2013.51. Epub 2013 May 20. Review.

3.

Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis.

Patwardhan CA, Fauq A, Peterson LB, Miller C, Blagg BS, Chadli A.

J Biol Chem. 2013 Mar 8;288(10):7313-25. doi: 10.1074/jbc.M112.427328. Epub 2013 Jan 25.

4.

Benchmarking ligand-based virtual High-Throughput Screening with the PubChem database.

Butkiewicz M, Lowe EW Jr, Mueller R, Mendenhall JL, Teixeira PL, Weaver CD, Meiler J.

Molecules. 2013 Jan 8;18(1):735-56. doi: 10.3390/molecules18010735.

5.

Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133.

Wang HR, Wu M, Yu H, Long S, Stevens A, Engers DW, Sackin H, Daniels JS, Dawson ES, Hopkins CR, Lindsley CW, Li M, McManus OB.

ACS Chem Biol. 2011 Aug 19;6(8):845-56. doi: 10.1021/cb200146a. Epub 2011 Jun 13.

6.

NADPH oxidase (NOX) isoforms are inhibited by celastrol with a dual mode of action.

Jaquet V, Marcoux J, Forest E, Leidal KG, McCormick S, Westermaier Y, Perozzo R, Plastre O, Fioraso-Cartier L, Diebold B, Scapozza L, Nauseef WM, Fieschi F, Krause KH, Bedard K.

Br J Pharmacol. 2011 Sep;164(2b):507-20. doi: 10.1111/j.1476-5381.2011.01439.x.

7.

Bioluminescence assay for detecting cell surface membrane protein expression.

Kato M, Chiba T, Li M, Hanyu Y.

Assay Drug Dev Technol. 2011 Feb;9(1):31-9. doi: 10.1089/adt.2010.0278. Epub 2010 Sep 13.

8.

Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions.

Gao Z, Zhang T, Wu M, Xiong Q, Sun H, Zhang Y, Zu L, Wang W, Li M.

J Biol Chem. 2010 Sep 3;285(36):28322-32. doi: 10.1074/jbc.M110.116392. Epub 2010 Jun 28.

9.

Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities.

Bhave G, Lonergan D, Chauder BA, Denton JS.

Future Med Chem. 2010 May;2(5):757-74. doi: 10.4155/fmc.10.179. Review.

10.

Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.

Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, Aggarwal BB, Liu M.

Cancer Res. 2010 Mar 1;70(5):1951-9. doi: 10.1158/0008-5472.CAN-09-3201. Epub 2010 Feb 16.

11.

Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23.

Chadli A, Felts SJ, Wang Q, Sullivan WP, Botuyan MV, Fauq A, Ramirez-Alvarado M, Mer G.

J Biol Chem. 2010 Feb 5;285(6):4224-31. doi: 10.1074/jbc.M109.081018. Epub 2009 Dec 8.

12.

Specific and slow inhibition of the kir2.1 K+ channel by gambogic acid.

Zaks-Makhina E, Li H, Grishin A, Salvador-Recatala V, Levitan ES.

J Biol Chem. 2009 Jun 5;284(23):15432-8. doi: 10.1074/jbc.M901586200. Epub 2009 Apr 13.

13.

Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon?

van der Heyden MA, Smits ME, Vos MA.

Br J Pharmacol. 2008 Feb;153(3):406-9. Epub 2007 Dec 3.

14.

Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.

Takemasa H, Nagatomo T, Abe H, Kawakami K, Igarashi T, Tsurugi T, Kabashima N, Tamura M, Okazaki M, Delisle BP, January CT, Otsuji Y.

Br J Pharmacol. 2008 Feb;153(3):439-47. Epub 2007 Oct 29.

15.

Mechanisms of cardiac potassium channel trafficking.

Steele DF, Eldstrom J, Fedida D.

J Physiol. 2007 Jul 1;582(Pt 1):17-26. Epub 2007 Apr 5. Review.

16.

Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, January CT.

Br J Pharmacol. 2006 Nov;149(5):481-9. Epub 2006 Sep 11.

Items per page

Supplemental Content

Write to the Help Desk